Edge Therapeutics
NJIT-EDC Biotechnology Incubator
139 South Street, Suite 102
New Providence
New Jersey
07974
United States
Tel: 800-208-EDGE
Fax: 800-208-3433
Website: http://www.edgetherapeutics.com/
Email: info@edgetherapeutics.com
61 articles about Edge Therapeutics
-
Edge Therapeutics Grabs $10 Million Venture Loan
9/8/2014
-
Edge Therapeutics Initiates Enrollment Of Second Cohort In Phase 1/2 NEWTON Study Of EG-1962 For Improvement Of Outcome After Ruptured Brain Aneurysm
6/5/2014
-
Edge Therapeutics Expands Senior Management Team And Opens New Headquarters To Support Continued Growth
4/8/2014
-
Edge Therapeutics Enrolls First Patient in Phase 1/2 NEWTON Study of EG-1962 for Prevention of Delayed Cerebral Ischemia
10/31/2013
-
Edge Therapeutics Elects Robert J. Spiegel, MD to Board of Directors
9/10/2013
-
Vasospasm 2013 Conference Features Oral Presentation of Edge Therapeutics’ EG-1962
7/12/2013
-
Edge Therapeutics Reports Positive Early Clinical Experience With EG-1962 to Prevent Serious Complications After Brain Hemorrhage
6/27/2013
-
FDA Accepts IND Application for Edge Therapeutics' EG-1962 (nimodipine microparticles)
6/10/2013
-
Edge Therapeutics Banks $18 Million
6/4/2013
-
Edge Therapeutics Appoints Dr. Sol Barer and Isaac Blech as Chairman and Vice Chairman of Its Board of Directors
1/23/2013
-
Edge Therapeutics Appoints Drug-Delivery Luminary Dr. Robert Langer to Chair Scientific Advisory Committee
8/22/2012
-
Government of Canada Awards CA$700,000 Toward Phase 2 Study of Edge Therapeutics's Lead Compound to Improve Outcomes After Brain Injury
6/11/2012
-
MPI Research and Edge Therapeutics Partner to Advance Development of Life-Saving Therapies After Brain Hemorrhage
4/3/2012
-
Edge Therapeutics Receives Success Award From New Jersey Small Business Development Centers
12/5/2011
-
Edge Therapeutics Appoints James J. Loughlin to Board of Directors
11/17/2011
-
Edge Therapeutics to Present at Rodman & Renshaw's 13th Annual Healthcare Conference
9/7/2011
-
Edge Therapeutics Appoints Dr. Sol J. Barer to Board of Directors
9/7/2011
-
Edge Therapeutics Release: NimoGel(TM) Shows Promise at Preventing Delayed Complications of Sudden Brain Injury in a Preclinical Study Presented at the International Stroke Conference
2/14/2011
-
SurModics Inc. and Edge Therapeutics Collaborate on Development of Sustained-Release Neurological Product
11/4/2010
-
Edge Therapeutics and SurModics Inc. Collaborate to Develop a Drug Delivery Technology for Treatment of Secondary Brain Injury After Stroke or Traumatic Brain Injury (TBI)
7/20/2010